> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Harpoon Therapeutics Orphan Status for Myeloma Drug
- URL: https://www.fdaweb.com/harpoon-therapeutics-orphan-status-for-myeloma-drug/
- Published: 2021-01-13T12:00:00.000Z
- Updated: 2026-09-14T16:42:22.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148445

FDA has granted Harpoon Therapeutics an orphan drug designation for HPN217 for treating multiple myeloma. The tri-specific T cell activating recombinant protein construct targets B-cell maturation antigen, which is expressed on malignant multiple myeloma cells, the company says. Last April, Harpoon announced dosing of the first patient with HPN217 in a Phase 1/2 clinical trial focused on relapsed/refractory multiple myeloma. HPN217 has been well tolerated, and no dose limiting toxicities were observed up to the most recent data cutoff date (12/1/2020), the company says. A presentation of interim data is expected later this year, and the initiation of a dose expansion cohort in the second half of this year is planned.